JP2017506259A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506259A5
JP2017506259A5 JP2016567288A JP2016567288A JP2017506259A5 JP 2017506259 A5 JP2017506259 A5 JP 2017506259A5 JP 2016567288 A JP2016567288 A JP 2016567288A JP 2016567288 A JP2016567288 A JP 2016567288A JP 2017506259 A5 JP2017506259 A5 JP 2017506259A5
Authority
JP
Japan
Prior art keywords
inhibitor
cml
use according
cki
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2015/050118 external-priority patent/WO2015114638A2/en
Publication of JP2017506259A publication Critical patent/JP2017506259A/ja
Publication of JP2017506259A5 publication Critical patent/JP2017506259A5/ja
Pending legal-status Critical Current

Links

JP2016567288A 2014-02-03 2015-02-03 幹細胞を枯渇させるためのカゼインキナーゼi阻害剤の使用 Pending JP2017506259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934954P 2014-02-03 2014-02-03
US61/934,954 2014-02-03
PCT/IL2015/050118 WO2015114638A2 (en) 2014-02-03 2015-02-03 Method of eliminating stem cells

Publications (2)

Publication Number Publication Date
JP2017506259A JP2017506259A (ja) 2017-03-02
JP2017506259A5 true JP2017506259A5 (enExample) 2018-03-22

Family

ID=52589722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567288A Pending JP2017506259A (ja) 2014-02-03 2015-02-03 幹細胞を枯渇させるためのカゼインキナーゼi阻害剤の使用

Country Status (7)

Country Link
US (2) US20170042893A1 (enExample)
EP (1) EP3102192A2 (enExample)
JP (1) JP2017506259A (enExample)
CN (2) CN106470699A (enExample)
AU (2) AU2015212341A1 (enExample)
CA (1) CA2937992A1 (enExample)
WO (1) WO2015114638A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722513B2 (en) 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
US20190070183A1 (en) * 2015-11-04 2019-03-07 The Trustees Of Columbia University In The City Of New York Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
MX2021002652A (es) * 2018-09-09 2021-09-23 Qanatpharma Ag Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
EP3877382B1 (en) 2018-11-07 2026-03-18 Tianli Biotech Pty Ltd Novel compounds for the treatment of respiratory diseases
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6946445B1 (en) 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2001057189A2 (en) * 2000-02-07 2001-08-09 Quark Biotech, Inc. Fas pathway genes
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
AU2001284419A1 (en) 2000-09-05 2002-03-22 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US20050171005A1 (en) * 2002-04-29 2005-08-04 Yinon Ben-Neriah Methods and compositions for modulating beta-catenin phosphorylation
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Cxcr4アンタゴニストおよびそれらの使用方法
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
EP1697715A4 (en) 2003-12-05 2007-10-10 Univ Leland Stanford Junior IDENTIFICATION, ISOLATION AND ELIMINATION OF CANCER STEM CELLS
EP2298292A3 (en) 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
WO2008132234A2 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
US9623109B2 (en) * 2008-05-27 2017-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of killing cells and use of same in prevention and treatment of cancer
CZ2012538A3 (cs) * 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie

Similar Documents

Publication Publication Date Title
Ladikou et al. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
Cho et al. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
Chen et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy
Ravandi Relapsed acute myeloid leukemia: why is there no standard of care?
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
FI3694529T3 (fi) Trispesifiset proteiinit ja niiden käyttömenetelmät
JP2019506403A5 (enExample)
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
KR20150080592A (ko) Tec 패밀리 키나제 억제제 애쥬번트 요법
JP2020505433A5 (enExample)
Blomberg et al. Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review
Cuglievan et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
JP2018522038A5 (enExample)
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
Roganovic Acute lymphoblastic leukemia in children
Wang et al. β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia
JP2017519006A5 (enExample)
Palmisiano et al. Polo‐like kinase and its inhibitors: Ready for the match to start?
Cai et al. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response
Sgambato et al. Medical treatment of small cell lung cancer: state of the art and new development
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
Gillison et al. Cancer chemotherapy in the elderly patient
Krawczyk et al. The role of inflammation in leukaemia
Edelman Gemcitabine and Carboplatin Regimens in Advanced Non–Small-Cell Lung Cancer: Focus on Randomized Phase III Trials
Pilehvari et al. The role of genetics and synergistic effect of targeting common genetic mutations in Acute Lymphoblastic Leukemia (ALL)